ENGLEWOOD, Colo., Jan. 31, 2023 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced The Healthcare Technology Report has recognized Zynex in The Power 500 Healthcare Technology Companies.
"We are honored to be included in The Power 500 alongside some of the most innovative and well-known organizations in healthcare. Zynex ranked 27th among medical device companies and we believe this distinction solidifies our position as leaders in the category," said Thomas Sandgaard, CEO of Zynex. "Our consistent operational performance is the result of a committed team striving to improve the health of our patients. I'm proud of this recognition and look forward to many years of innovation and growth."
About The Healthcare Technology Report
The Healthcare Technology Report (HLTR) provides market research and insights, business news, investment activity updates, and important corporate developments related to the healthcare technology sector. Based in New York City, the firm is run by a seasoned team of editors, writers, and media professionals highly knowledgeable on healthcare technology and the various companies, executives, and investors that make up the sector.
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com
Investor Contact
Gilmartin Group
650 Fifth Ave., Suite 2720
New York, NY 10019
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$1.39 |
Daily Change: | 0.01 0.72 |
Daily Volume: | 13,744 |
Market Cap: | US$42.120M |
October 14, 2025 August 18, 2025 July 31, 2025 June 30, 2025 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load